Identification of a novel class of autotaxin inhibitors through cross-screening†
Abstract
Three novel series were generated in order to mimic the pharmacophoric features displayed by lead compound AM095, a
* Corresponding authors
a
WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow, UK
E-mail:
craig.jamieson@strath.ac.uk, allan.watson.100@strath.ac.uk
b Strathclyde Institute of Pharmacy and Biomolecular Science, University of Strathclyde, John Arbuthnott Building (Hamnett Wing), 161 Cathedral Street, Glasgow, UK
c Fibrosis DPU, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK
Three novel series were generated in order to mimic the pharmacophoric features displayed by lead compound AM095, a
D. Castagna, E. L. Duffy, D. Semaan, L. C. Young, J. M. Pritchard, S. J. F. Macdonald, D. C. Budd, C. Jamieson and A. J. B. Watson, Med. Chem. Commun., 2015, 6, 1149 DOI: 10.1039/C5MD00081E
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content